Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Metabolic Inflammation as a Common Thread in Cardio-Endocrine Diseases: Toward a Unified Therapeutic Framework.

Patil N., Uppal N., Bedi S., Undhad H., Joshi P.

Narrative Review on Type 2 Diabetes, Chronic Inflammation, published in Cureus (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Cureus (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41732594
DOI
10.7759/cureus.102160

Abstract (original English)

Metabolic inflammation, or metaflammation, has emerged as a unifying mechanism linking cardiovascular and endocrine disorders. This narrative review aimed to synthesize mechanistic, clinical, and therapeutic evidence on how inflammation bridges these domains and to explore prospects for a unified therapeutic framework. We systematically searched PubMed, Scopus, and Web of Science for English-language articles published between 2010 and 2024, yielding 256 relevant articles, of which 115 were included after detailed screening. Studies addressing adipose tissue inflammation, gut microbiota dysbiosis, innate immune activation, mitochondrial dysfunction, clinical biomarkers, and anti-inflammatory therapies were analyzed. Evidence demonstrates that visceral adipose tissue (VAT) inflammation, inflammasome activation, and mitochondrial oxidative stress form shared pathogenic nodes across cardiovascular and endocrine diseases. Clinical correlates, including biomarkers such as IL-6, C-reactive protein (CRP), glycoprotein acetylation (GlycA), and exosomes, provide diagnostic and prognostic insights, while therapeutic convergence has been highlighted by sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and IL-1β-targeted interventions. Lifestyle modifications such as Mediterranean diets, microbiota-directed therapies, and intermittent fas

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research